US Stock MarketDetailed Quotes

RLMD Relmada Therapeutics

Watchlist
  • 0.452
  • -0.023-4.76%
Close Jan 8 16:00 ET
  • 0.463
  • +0.011+2.37%
Post 17:24 ET
13.64MMarket Cap-0.16P/E (TTM)

Relmada Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Relmada Therapeutics Q3 2024 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
EPS
-0.64
-0.72
-0.08
Miss Est.
+12.33%
+1.37%
-12.52%
Net Income
--
-21.73M
--
+1.25%
Analyst Rating
Buy

Dec 31, 2024

Relmada Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 7, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 7, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Relmada Therapeutics Earnings Reports

  • Relmada Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 8, 2024 05:10

  • Relmada Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8, 2024 04:10

  • Relmada Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 9, 2024 04:13

  • Relmada Therapeutics | 8-K: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

    Mar 20, 2024 04:14

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 31, 2024

    Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data